Recruiting Advanced Solid Tumors Studies in Canton
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1305/BNT325 in subjects with advanced solid tumors....
XTX301 in Patients With Advanced Solid Tumors
This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors....
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This is a first-in-human, open-label, Phase 1/2, dose escalation and dose exp...
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
KB707-01 is a Phase 1/2, open-label, multicenter, dose escalation and expansion study. The study will evaluate the safety and tolerability of KB707 in adults with locally advanced or metastatic solid ...
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation....
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
INDP-D101 is a Phase 1/2, open-label, multi-center, dose escalation and expansion study evaluating the safety, tolerability and clinical activity of Decoy20 as monotherapy and in combination with tisl...
A Study of HB0045 Injection in Patients With Advanced Solid Tumors
This is a phase I/II, open-label, multicenter study . During the study, subjects will be evaluated for safety, toxicity, tolerability, PK/PD, immunogenicity, biomarkers, and antitumor activity of HB00...
Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors
The objective of this study is to assess the safety, efficacy, and pharmacokinetics of SA53-OS in adult participants with refractory solid tumors. The study is comprised of 2 parts: Part 1 called dos...
About Advanced Solid Tumors Clinical Trials in Canton
Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.
There are currently 8 advanced solid tumors clinical trials recruiting participants in Canton, OHIO. These studies are seeking a combined 2,471 participants. Research is being sponsored by DualityBio Inc., Xilio Development, Inc., Ascendis Pharma Oncology Division A/S and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Advanced Solid Tumors Clinical Trials in Canton — FAQ
Are there advanced solid tumors clinical trials in Canton?
Yes, there are 8 advanced solid tumors clinical trials currently recruiting in Canton, OHIO. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Canton?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Canton research site will contact you about next steps.
Are clinical trials in Canton free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Canton studies also compensate for your time and travel.
What advanced solid tumors treatments are being tested?
The 8 active trials in Canton are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.
Data updated March 2, 2026 from ClinicalTrials.gov